RxDoctor Payments Data

Lindsay Callaghan

Family · Fredericksburg, VANPI 1356790257

Payments from drug & device makers

$2,022in general payments, 2019–2025

Across 67 payments — averaging $30.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$407
  • Boston Scientific$368
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
  • Novo Nordisk$162
  • Abiomed$155
  • Abbott$123
  • plus $600 from 18 others

What the payments were for

  • Food & beverage$2,022100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,022 in reported general payments places this provider in the 80th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$3,802
Medicare patients
33
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$163,441
EntrestoSacubitril/Valsartan41$57,116
Repatha SureclickEvolocumab54$49,839
XareltoRivaroxaban22$35,320
Rosuvastatin Calcium196$3,234
Metoprolol Succinate227$3,125
Flecainide Acetate35$2,341
Atorvastatin Calcium208$1,963
Nebivolol Hcl30$1,503
Ezetimibe47$1,483
Bumetanide37$1,355
Carvedilol152$1,236
Midodrine Hcl17$1,159
Amlodipine Besylate173$1,093
ClopidogrelClopidogrel Bisulfate90$968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$163,441130 claims
NovartisEntresto$28$57,11641 claims
Johnson & JohnsonXarelto$27$35,32022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,332 family providers in Virginia.

Other family in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →